8P.Lietal./ColloidsandSurfacesA:Physicochem.Eng.Aspects392 (2011) 7–15

2H

2
3
H3
2
Fig.1.ThestructureofADMandDNR.
2
whichcanbindwithDNAandrestrainitssynthesis,isapotentantioxidantleukemiadrugs.ToxicitystudyhasmanifestedthatifDNRwasspilledwhichwillcausetissuenecrosis[12].
HPLCisthemostwidelyemployedmethodforthedeter-minationofAQanticancerdrugs[13,14].Moreover,capillaryelectrophoresis[15,16],electrochemistry[17],HPLC–MS[18]andimmunoassay[19]arealsoreported.However,spectralmethodswererelativelyfewer.Onlyspectrophotometry[20],Ramanscat-teringmethods[21,22]andresonanceRayleighscattering[23]werereportedandmostofthemsufferedfromlowsensitivityorbadspeci cityorcomplicatedprocess.Therefore,itisimportanttodevelopfurthersensitive,speci candsimplespectralmethodsforthedeterminationofAQanticancerdrugs.
Inthiswork,theinteractionofCdTe/CdSQDs-AQanticancerdrugs-hsDNAwasinvestigatedbasedonluminescentofCdTe/CdSQDs.TheresultsindicatedthatAQanticancerdrugseffectivelyquenchedtheFLCdTe/CdSQDsviaPETprocess.TheadditionofhsDNAbroughttherestorationofCdTe/CdSQDsFLintensity.CdTe/CdSQDsasprobe,asensitiveandsimplesystemforthedeterminationofAQanticancerdrugsandhsDNAwasdevelopedaccordingtotheFLreversiblecontrolofCdTe/CdSQDs.Thereac-tionmechanismofCdTe/CdSQDs-AQanticancerdrugs-hsDNAwasdiscussedindetail.
grainsizesandsurfacetopographyofCdTe/CdSQDsweremea-suredbyatomicforcemicroscopy(AFM,NanoScopequadrex,veccoCorporationAmerican,TappingMode,pinpoint:TESP7Vecco.).APHSJ-3FpHmeter(Leici,Shanghai)wasusedtoadjustpH.
2.3.PreparationofCdTe/CdSQDs
2.Experimental
2.1.Reagentsandmaterials
CdCl2·2.5H2O,thioglycollicacidandthioacetamide(TAA)werepurchasedfromShanghaiChemicalsReagentCo.,Shanghai.TepowderwaspurchasedfromSinopharmChemicalReagentCo.,Shanghai.NaBH4waspurchasedfromTianjinHuanweiFineChem-icalCo.,Tianjin.Tris–HClbuffersolutionwasusedtocontroltheacidityofthereaction,whichwaspreparedbymixing0.1molL 1HCland0.1molL 1tromethamine(Tris)solutionaccordingtocer-tainproportion.Adriamycin(ADM)waspurchasedfromZhejiangHaizhengChinaPharmaceuticalCo.,Ltd.,Daunorubicin(DNR)waspurchasedfromPharmaciaItaliaS.P.A.Allreagentswereanalyticalgradewithoutfurtherpuri cationanddeionizedwaterwasusedthroughout.
AqueouscolloidsCdTe/CdSQDssolutionwaspreparedatlowtemperatureaccordingtothereference[24].Itwasdescribedindetailasfollows:underN2atmosphere,deionizedwater(10mL)wasaddedtoTepowder(0.0191g)andexcessiveNaBH4undermagneticstirringatroomtemperature.Afterabout2h,thecol-orlesssolutionofNaHTewasprepared.
0.1370gCdCl2·2.5H2Owasdissolvedin150mLofdeionizedwaterand80 LofTGAstabilizerwasaddedunderstirring,fol-lowedbyadjustingtopH=11bydropwisingadditionof1molL 1NaOHsolution.Thesolutionwasplacedinathree-necked askanddeaeratedbyN2bubblingforabout30min.Undermagneticstir-ring,H2TegasgeneratedbythereactionofthesolutionofNaHTewithdilutedH2SO4(0.5molL 1)waspassedthroughtheoxygen-freeoriginalsolutiontogetherwithaslowN2 owfor30min.CdTeprecursorswereformedatthisstage.ThemolarratioofCd2+/TGA/HTe was xedat1:2:0.25.Thentheresultingmixturewassubjectedtore uxat96 Cfor2hunderoxygen-freeconditionwithcondenser.
AtypicalsynthesisofCdTe/CdSQDswithTAAassulfursourcewasdescribedhereafter.The150mlofas-preparedTGA-CdTeQDssolutionwasheatedto96 Cunderoxygen-freeconditionwithcon-denser,andthen0.054mmolofTAAwasadded.Thesolutionwasre uxedfor1hunderoxygen-freeconditionwithcondensertheCdTe/CdSQDswasobtained.TheconcentrationofCdTe/CdSQDswas2×10 3molL 1(determinedbytheTe2 concentration)[25].
2.4.TheinteractionofCdTe/CdSQDswithAQanticancerdrugs
1.4mLabovepreparedCdTe/CdSQDs,1.3mLpH=7.1Tris–HClandappropriateamountsofADMorDNRwereaddedintoa10mLvolumetric ask,thendilutedwithdeionizedwatertothemarkandmixedthoroughlywithgentleshake.Afterincubatedfor5min,theFL,RRS,UV–visabsorptionspectraofsolutionwereexamined.
2.2.Apparatus
2.5.TheinteractionofCdTe/CdSQDs-AQanticancerdrugswithhsDNA
AHitachiF-2500spectro uorophotometer(HitachiCompany,Japan)wasusedtorecordtheresonanceRayleighscattering(RRS)( ex= em)andFLspectra(excitationwavelength =350nm).AUV-2450spectrophotometer(TianmeiCorporation,Shanghai)wasappliedtorecordtheultraviolet(UV–vis)absorptionspectra.The
1.4mLabovepreparedCdTe/CdSQDs,1.3mLpH=7.1Tris–HCland1.8mL(50 gmL 1)ADMorDNRwereaddedintoa10mLvolu-metric ask.Afterreactedfor5min,appropriateamountsofhsDNAwasaddedabovesolution,thendilutedwithdeionizedwatertothe
蒽醌类 抗癌药物心脏毒理研究 逊业 飞高 7 川 中国围书分类号 R92R99. 6{ 7. 醌 类抗 癌药 物中的 新成 员, 以其效 高, 心脏 毒性低 而成为 醌类...
生物制药---抗癌药物研究_小学教育_教育_PPT专区。抗癌药物研究:各种动植物在...苯并蒽醌类 八、双烯二炔类 九、激素类 十、其他微生物代谢物 一、多肽及...
蒽醌核邻位和间位羟基具有明显抗 5$T 作用, 低 $ 9 糖蛋白的功能和表达, 提高抗癌药物在癌细胞中的浓度而 优于同剂量维生素 <, 有较强的清除 >B 作用 ...
8、 米托蒽醌 二氢基蒽醌 MIT 用后巩膜可呈蓝色,尿呈篮绿色,粪呈黄绿色. 注 射剂 5mg10mg20mg30mg 9、丙卡巴肼 甲基苄肼 PCB 三、常用的抗癌分子靶向药物...
基因治疗 ? 综合疗法:如手术+药物(放射) 4.抗癌药的分类:⑴按结构和来源分:...抗癌三角形结构药效基团:N—O—O三角形环状结构 蒽醌为母核,其它氨基(或烃...
9,10-蒽醌类衍生物的合成及抑菌活性测定作者: 指导教师: 摘要:羟基蒽醌类化合物是虎杖、大黄和决明子等中药的主要有效成分之一,具有一定的抗癌、抗炎和抗菌等活性...
二羟基蒽醌系列 中间体 的合成 及其 性质 研究 , 蒽醌型 抗癌新 药 的设计 合成 为提 供原 料 和相 关 制备 、质 理论 具有 重要 意义.者 性笔 N ...
抗癌微生物药物的研究与开发_临床医学_医药卫生_专业资料。抗癌微生物药物的...1.5 氨茴霉素类(Anthramycins)抗生素 1.6 苯骈蒽醌类(Benz[a]anthra...
[0011] 本发明还提供一种具有抗癌作用的药物, 该药物是用上述白花蛇舌草提取物...单溶液细胞增殖检测 (MTS) 试剂盒测定了该组分中分离得到的 蒽醌类和三萜类...
米托蒽醌属于蒽环类抗癌药物 ,用于治疗乳腺癌和白血病 。武五爱等 以邻氨基酚为聚 合单体 ,得到米托蒽醌分子印迹电化学传感器 ,该传感器用于药物分析中米托...
热门文档